

***Fiscal Year 2025 Department of Defense Breast Cancer Research Program (BCRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Breakthrough Award Levels 1 and 2</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT942525BCRPBTA12</p>	<p>Investigators at all academic levels (or equivalent).</p> <p>Applications from postdoctoral fellows are encouraged.</p> <p>Each investigator may be named as a Principal Investigator (PI) on only one application per funding level for the Breakthrough Award Levels 1 and 2.</p>	<ul style="list-style-type: none"> <li>Supports promising research with high potential to lead to or make breakthroughs in breast cancer.</li> <li>The impact may be near-term or long-term but must go beyond a minor advancement and have the potential to lead to a fundamentally new strategy or approach for preventing or ending breast cancer that is significantly more effective than current strategies or approaches.</li> <li><b>Partnering PI Option:</b> Supports meaningful and productive partnerships between two investigators referred to as the Initiating PI and the Partnering PI.</li> </ul> <p>The following are general descriptions, although not all-inclusive, of the scope of research projects appropriate for each funding level:</p> <ul style="list-style-type: none"> <li><b>Funding Level 1:</b> Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are <b>not</b> required. Proof of concept is the anticipated outcome.</li> <li><b>Funding Level 2:</b> Research that is already supported by substantial preliminary or published data <i>in breast cancer</i> and strongly validates clinical translation in a well-defined context within the <i>breast cancer landscape</i>.</li> <li><b>Funding Level 2 – Population Science and Prevention Studies:</b> Studies focused on the analysis of human data and biospecimens. Research should be supported by substantial preliminary or published data <i>in breast cancer</i> and strongly validate clinical translation in a well-defined context within the <i>breast cancer landscape</i>.</li> </ul> <p><b><u>Funding Levels 1 and 2</u></b></p> <ul style="list-style-type: none"> <li>Submission of a Letter of Intent is required prior to full application submission.</li> </ul>	<p><b>Funding Level 1:</b></p> <ul style="list-style-type: none"> <li>Maximum allowable funding: <ul style="list-style-type: none"> <li><b>Single PI: \$540,000</b> for direct costs (plus indirect costs)</li> <li><b>Partnering PI Option: \$900,000</b> for direct costs (plus indirect costs)</li> </ul> </li> <li>The maximum period of performance is <b>3</b> years.</li> </ul> <p><b>Funding Level 2:</b></p> <ul style="list-style-type: none"> <li>Maximum allowable funding: <ul style="list-style-type: none"> <li><b>Single PI: \$1.2 million (M)</b> for direct costs (plus indirect costs)</li> <li><b>Partnering PI Option: \$1.8M</b> for direct costs (plus indirect costs)</li> <li><b>Population Science and Prevention Studies with Single PI: \$1.8M</b> for direct costs (plus indirect costs)</li> <li><b>Population Science and Prevention Studies with Partnering PI Option: \$2.4M</b> for direct costs (plus indirect costs)</li> </ul> </li> <li>The maximum period of performance is <b>3</b> years.</li> <li>The maximum period of performance for Funding Level 2 - Population Science and Prevention Studies is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> June 13, 2025 5:00 p.m. Eastern time</p> <p><b>Application:</b> June 27, 2025 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Research Extension Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942525BCRPREA</p>	<p>Independent investigators at all academic levels (or equivalent).</p>	<ul style="list-style-type: none"> <li>• Supports the extension or expansion of data collection, follow-up, and analysis of breast cancer clinical studies.</li> <li>• Intended to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis.</li> <li>• Although not all inclusive, the scope of research that this award mechanism supports includes projects entailing a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis-testing or -generating or may be designed to generate clinically annotated and molecularly characterized experimental platforms, including patient-derived models or tissue arrays. Innovation is not a criterion for this award mechanism.</li> <li>• <b>Partnering PI Option:</b> Supports meaningful and productive partnerships between two investigators referred to as the Initiating PI and the Partnering PI.</li> </ul> <p><b><u>Additional Elements</u></b></p> <ul style="list-style-type: none"> <li>• Submission of a Letter of Intent is required prior to full application submission.</li> <li>• Applications must include two or more breast cancer consumer advocates on the research team.</li> </ul>	<ul style="list-style-type: none"> <li>• Maximum allowable funding: <ul style="list-style-type: none"> <li>○ <b>Single PI: \$5M</b> for direct costs (plus indirect costs)</li> <li>○ <b>Partnering PI Option: \$6M</b> for direct costs (plus indirect costs)</li> </ul> </li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> June 13, 2025 5:00 p.m. Eastern time</p> <p><b>Application:</b> June 27, 2025 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Era of Hope Scholar Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942525BCRPEOHS</p>	<p>Independent, non-mentored investigators within six years of their last training position as of the application submission deadline (excluding time spent on family medical leave).</p> <p>Postdoctoral fellows, clinical fellows (including residents and interns), and other researchers currently in training positions are not eligible.</p>	<ul style="list-style-type: none"> <li>Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer.</li> <li>Individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity.</li> <li>PIs should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research.</li> <li>Applications should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.</li> <li><i>Experience in breast cancer research is not required;</i> however, the application must focus on breast cancer, and the PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award.</li> </ul> <p><b><u>Additional Elements</u></b></p> <ul style="list-style-type: none"> <li>Submission of a Letter of Intent is required prior to full application submission.</li> <li>Applications must include two or more breast cancer consumer advocates on the research team.</li> </ul>	<ul style="list-style-type: none"> <li>Maximum allowable funding: <b>\$3.5M</b> for direct costs (plus indirect costs)</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> June 13, 2025 5:00 p.m. Eastern time</p> <p><b>Application:</b> June 27, 2025 11:59 p.m. Eastern time</p> <p><b>Confidential Letters of Recommendation Submission Deadline:</b> July 2, 2025 5:00 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Breakthrough Award Level 3</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942525BCRPBTA3</p>	<p>Independent investigators at all academic levels (or equivalent).</p>	<ul style="list-style-type: none"> <li>Supports promising research with high potential to lead to or make breakthroughs in breast cancer.</li> <li>Research must have the potential for a major impact and accelerate progress toward ending breast cancer.</li> <li>The impact may be near-term or long-term but must go beyond a minor advancement and have the potential to lead to a fundamentally new strategy or approach for preventing or ending breast cancer that is significantly more effective than current strategies or approaches.</li> <li><b>Partnering PI Option:</b> Supports meaningful and productive partnerships between two investigators referred to as the Initiating PI and the Partnering PI.</li> </ul> <p>The following is a general description, although not all-inclusive, of the scope of research projects appropriate for <b>Funding Level 3</b>:</p> <ul style="list-style-type: none"> <li>Advanced translational studies. Where relevant, the proposed research must be supported by proof of availability of, and access to, necessary data, human samples, cohort(s) and/or clinical reagents. If the proposed research will ultimately require U.S. Food and Drug Administration or an equivalent international regulatory agency involvement, the project must be supported by demonstrated availability of, and access to, clinical reagents (e.g., therapeutics) and subject population(s). A realistic timeline for near-term clinical research as defined in the program announcement must be stated. Small-scale clinical trials may be appropriate.</li> </ul> <p><u><b>Additional Elements</b></u></p> <ul style="list-style-type: none"> <li><i>Pre-application submission is required; application submission is by invitation only.</i></li> <li>Applications must include two or more breast cancer consumer advocates on the research team.</li> </ul>	<ul style="list-style-type: none"> <li>Maximum allowable funding: <ul style="list-style-type: none"> <li><b>Single PI: \$4M</b> for direct costs (plus indirect costs)</li> <li><b>Partnering PI Option: \$5M</b> for direct costs (plus indirect costs)</li> </ul> </li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> June 13, 2025 5:00 p.m. Eastern time</p> <p><b>Application:</b> September 10, 2025 11:59 p.m. Eastern time</p>